Description
Clinical Evidence
• In the SURPASS clinical trial series, tirzepatide led to A1C reductions up to 2.5% and average weight loss exceeding 22% in some study arms—results that surpassed both placebo and semaglutide.
• SURPASS-2, a direct comparison trial, showed tirzepatide outperformed semaglutide in both glycemic control and weight reduction.
• Preliminary data from SURMOUNT trials suggest promising applications in non-diabetic obesity, indicating its broader metabolic impact.
Potential Side Effects
Most side effects are gastrointestinal and dose-dependent. These may include:
• Nausea and vomiting
• Diarrhea or constipation
• Decreased appetite
• Abdominal discomfort
• Injection site reactions
• Rarely: gallbladder issues or pancreatitis
Symptoms typically decrease with dose titration and continued use.
Disclaimer
This product is for research use only and is not approved for human or animal consumption. It should only be used by qualified personnel in a controlled laboratory environment. Information provided is for educational and informational purposes only and does not constitute medical advice.
Reviews
There are no reviews yet.